Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
08:01pm, Thursday, 26'th May 2022 GlobeNewswire Inc.
Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study
4 Analysts Have This to Say About Iovance Biotherapeutics
04:09pm, Tuesday, 24'th May 2022 Benzinga
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
Why Cellectis' Shares Rose 22.7% This Week
11:35pm, Friday, 20'th May 2022 The Motley Fool
The company bucked the recent downward trend for biotech companies.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
09:15pm, Friday, 20'th May 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
02:45pm, Friday, 06'th May 2022 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
12:02pm, Friday, 06'th May 2022
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Iovance Biotherapeutics, Inc. (IOVA) CEO Dr. Fred Vogt on Q1 2022 Results - Earnings Call Transcript
10:30pm, Thursday, 05'th May 2022
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2022 Results Conference Call May 5, 2022 4:30 PM ET Company Participants Sara Pellegrino - Vice President, Investor and Public Relations Dr. Fred Vogt -
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting
04:01pm, Wednesday, 27'th Apr 2022
SAN CARLOS, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022
11:30am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will rep
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022
07:30am, Tuesday, 26'th Apr 2022
SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will repor
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
08:01pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today an
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
04:01pm, Monday, 25'th Apr 2022
SAN CARLOS, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
09:15pm, Friday, 22'nd Apr 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today an
These 20 highly rated stocks are expected to rise at least 70% over the next year
10:42am, Wednesday, 20'th Apr 2022 MarketWatch
Favored companies include Uber, General Motors and Twilio.
Iovance: Onward To Approval
08:15am, Wednesday, 20'th Apr 2022
Whenever your stock tumbles due to a temporary issue, it will nearly always rebound at resolution in the ensuing months. Iovance Biotherapeutics' potency assay for lifileucel caused a huge haircut in
